NCT03792919 Cessation of Long Term NAs vs. Keeping on NAs Among CHB Patients (CNAVK)
| NCT ID | NCT03792919 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Humanity & Health Medical Group Limited |
| Condition | Chronic Hepatitis B |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2018-12-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 2,000 participants in total. It began in 2018-12-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To Identify the collected cases who can stop NAs safely with satisfactory clinical outcome including sustain viral remission and HBsAg clearance among chronic hepatitis B(CHB) patients.
Eligibility Criteria
Inclusion Criteria: 1. HBsAg positive, HBeAg negative, antibody to HBeAg-positive; 2. Stable administration of anti-HBV neucleos(t)ides analogue mono therapy for at least more than one and a half year; 3. Demonstration of undetectable HBV DNA on three occasions, each at least 6 months apart, which is consistent with the APASL stopping rule; 4. Patients read, understand the consent form, and signed the study consent. Exclusion Criteria: 1. Patient with other liver diseases; 2. Patient with concurrent hepatitis viruses or HIV infection; 3. Patients are reluctant to stop their anti-HBV treatment.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03792919 clinical trial?
This trial is open to participants of all sexes, studying Chronic Hepatitis B. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT03792919 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT03792919 currently recruiting?
Yes, NCT03792919 is actively recruiting participants. Contact the research team at gkklau@netvigator.com for enrollment information.
Where is the NCT03792919 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT03792919 clinical trial?
NCT03792919 is sponsored by Humanity & Health Medical Group Limited. The trial plans to enroll 2,000 participants.